Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ARRY-371797 in active ankylosing spondylitis
2008-007510-30Phase 2Terminated
- Sponsor
- Array BioPharma
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emprumapimod in ankylosing spondylitis (AS) (3 arms), sponsored by Array BioPharma. Primary endpoint: ASAS 20 response at Week 12. Started Dec 2008; status: terminated.
02
Drugs
emprumapimod
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2008-007510-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007510-30.